Skip to main content

The logo for Shoppers Drug Mart is shown in downtown Toronto.

Eduardo Lima/The Canadian Press

Canadian cannabis producer Aphria Inc. has inked a deal to supply medical marijuana to Shoppers Drug Mart, the country's biggest chain of pharmacies.

Aphria and Shoppers have signed a five-year agreement that will see the Leamington, Ont.-based grower become the "first and preferred supplier of medical cannabis" to the pharmacy chain, Vic Neufeld, chief executive at Aphria, said late Monday on a conference call with analysts.

It's expected that Shoppers, which is owned by grocer Loblaw Cos. Ltd., will sell both dried bud and cannabis-infused oils to medical patients on the internet. Canadian regulations restrict the sale of medical marijuana in storefronts and pharmacies. The drug is sold today on the web and delivered to patients through the mail.

Story continues below advertisement

Specific financial terms of the deal were not disclosed. However, Aphria says its deal with the Canadian retail behemoth will boost its revenue and help bolster its brand with both existing cannabis users and doctors, who may now be more willing to consider prescribing cannabis to their patients.

"This is a big moment for Aphria," Mr. Neufeld said. "We have an opportunity to grow as Shoppers Drug Mart grows."

Shoppers is currently seeking approval from Health Canada to become a licensed producer to be able to sell these Aphria-branded products to medical users online. There is no timeline for if or when the federal government might approve its application. But the Aphria deal is conditional on Shoppers getting its licence.

The pharmacy chain says it doesn't plan on getting into the business of growing cannabis itself.

Canada is on track to legalize recreational cannabis in July, 2018. Provincial governments have tabled various regulatory regimes that could mean pot is sold in either publicly or privately run stores. Aphria says it hasn't talked to Shoppers about supplying cannabis for recreational use. "It's all been focused on medical," Mr. Neufeld said.

The company also has interests in the cannabis market south of the border, where the drug is legal in certain states but illegal federally.

The future of its stock listing on the Toronto Stock Exchange is uncertain after the TSX threatened in October to delist companies if they are deemed to be violating U.S. federal drug laws.

Story continues below advertisement

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.